Valbiotis announces the release of the Universal Registration Document

Regulatory News:

Valbiotis (FR0013254851 – ALVAL, PEA / SME eligible) (Paris:ALVAL), a commercially oriented Research and Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases, announces that its Universal Registration Document was filed to the French Financial Markets Regulator (AMF) April 26, 2023.

This document is made available to the public free of charge under the conditions provided for by current regulations and can be consulted and downloaded on the Valbiotis website (www.valbiotis.com/en/regulatory-information/). The Universal Registration Document is also available on the AMF website (www.amf-france.org).

About Valbiotis

Valbiotis is a commercially oriented Research & Development company, committed to scientific innovation for preventing and combating metabolic and cardiovascular diseases in response to unmet medical needs.

Valbiotis has adopted an innovative approach, aiming to revolutionize healthcare by developing a new class of health nutrition products designed to reduce the risk of major metabolic diseases, relying on a multi-target strategy enabled by the use of plant-based terrestrial and marine resources.

Internationally, its products are intended to be the subject of licensing and/or distribution agreements with global or regional health and nutrition players. In France, Valbiotis will be responsible for marketing its own products.

Created at the beginning of 2014 in La Rochelle, the Company has forged numerous partnerships with leading academic centers. The Company has established three sites in France – Périgny, La Rochelle (17) and Riom (63) – and a subsidiary in Quebec City (Canada).

Valbiotis is a member of the "BPI Excellence" network and has been recognized as an "Innovative Company" by the BPI label. Valbiotis has received major financial support from the European Union for its research programs via the European Regional Development Fund (ERDF). Valbiotis is a PEA-SME eligible company.

For more information about Valbiotis, please visit: www.valbiotis.com

Name: Valbiotis ISIN code: FR0013254851 Ticker symbol: ALVAL EnterNext© PEA-PME 150

This press release contains forward-looking statements about Valbiotis’ objectives. Valbiotis considers that these projections are based on rational hypotheses and the information available to Valbiotis at the present time. However, in no way does this constitute a guarantee of future performance, and these projections may be affected by changes in economic conditions and financial markets, as well as certain risks and uncertainties, including those described in the Valbiotis Universal Registration Document filed to the French Financial Markets Regulator (AMF) on April 26, 2023, this document is available on the Company's website (www.valbiotis.com).This press release and the information it contains do not constitute an offer to sell or subscribe, or a solicitation to purchase or subscribe to Valbiotis’ shares or financial securities in any country.

View source version on businesswire.com: https://www.businesswire.com/news/home/20230426005616/en/

Corporate communication / Valbiotis Carole ROCHER Communication and Public Affairs Director + 33 6 77 82 56 88

Marc DELAUNAY Communication Manager media@valbiotis.com

Financial communication / Seitosei Actifin Stéphane RUIZ Associate Director +33 1 56 88 11 14 sruiz@actifin.fr

Valbiotis (EU:ALVAL)
過去株価チャート
から 10 2024 まで 11 2024